Impact Factor
3.70
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.37
823 total citations
h5-index
30
h5 depth signal
Cited share
78.9%
157 of 199
Total citations
823
Citation footprint
Metric signal
3.54
External metric anchor
Self-citation
5.8%
48 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
South Korea
294
Japan
282
China
279
United States
196
Italy
68
Citing Fields of Research
Reproductive Health
914
Oncology
516
Obstetrics/Gynecology
178
Breast Cancer
58
Abdominal Surgery
42
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,622
Articles tracked across the journal lifetime
Indexed publication set
199
157 cited publications
Last 12 months
153
153.0 publications/month
Open access share
100.0%
153 OA publications in the last year
Leading citing country
South Korea
294 citing publications
Leading citing field
Reproductive Health
914 citing publications
Latest tracked publication
1 January 2027
10 recent records available
Coverage & Indexing History
v25n1, Jan. 2014-
v19n2, 2008-
Active Coverage
Research Focus & Classification
Indexed Subjects
Reproductive Health
Oncology
Issuing & Sponsoring Bodies
Contributor
Taehan Puin Chongyang Kolposŭkopi Hakhoe
Contributor
Korean Society of Gynecologic Oncology
Contributor
Asian Society of Gynecologic Oncology
Broad Categories
Gynecology
Neoplasms
Reproductive Health
MeSH Descriptors
Genital Neoplasms, Female
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.3802/jgo.2027.38.e22
Open DOI
Optimizing outcomes in minimally invasive radical hysterectomy: the protective role of a vaginal pipe
Kim S, et al. J Gynecol Oncol. 2027 ;38:e22. https://doi.org/10.3802/jgo.2027.38.e22
02
DOI 10.3802/jgo.2027.38.e34
Open DOI
Effectiveness of first-line niraparib maintenance in Korean patients with advanced ovarian cancer: a multicenter retrospective cohort study
Kang OJ, et al. J Gynecol Oncol. 2027 ;38:e34. https://doi.org/10.3802/jgo.2027.38.e34
03
DOI 10.3802/jgo.2027.38.e28
Open DOI
Correlation of bevacizumab relative dose intensity with first-line treatment outcomes in advanced epithelial ovarian cancer
Zhang L, et al. J Gynecol Oncol. 2027 ;38:e28. https://doi.org/10.3802/jgo.2027.38.e28
04
DOI 10.3802/jgo.2027.38.e30
Open DOI
Changes and clinical impact of HER3 and ERBB3 expression in primary and recurrent ovarian cancer
Yokosu K, et al. J Gynecol Oncol. 2027 ;38:e30. https://doi.org/10.3802/jgo.2027.38.e30
05
DOI 10.3802/jgo.2027.38.e24
Open DOI
Current status of fertility preservation for borderline ovarian tumor in Asian regions: results from ASGO-special task force for fertility preservation; part I. Fertility-sparing treatment for borderline ovarian tumor
Kuji S, et al. J Gynecol Oncol. 2027 ;38:e24. https://doi.org/10.3802/jgo.2027.38.e24
06
DOI 10.3802/jgo.2027.38.e21
Open DOI
Current status of fertility preservation for borderline ovarian tumor in Asian countries: results from ASGO-special task force for fertility preservation; part II. Fertility and pregnancy planning following initial treatment
Kuji S, et al. J Gynecol Oncol. 2027 ;38:e21. https://doi.org/10.3802/jgo.2027.38.e21
07
DOI 10.3802/jgo.2027.38.e27
Open DOI
Post-marketing safety assessment of mirvetuximab soravtansine: a disproportionality analysis based on the FDA Adverse Event Reporting System
Tan H, et al. J Gynecol Oncol. 2027 ;38:e27. https://doi.org/10.3802/jgo.2027.38.e27
08
DOI 10.3802/jgo.2027.38.e16
Open DOI
Prognosis and risk factors by histologic type of malignant ovarian germ cell tumors in Japan: a JSOG gynecologic tumor registry-based study
Sakaki H, et al. J Gynecol Oncol. 2027 ;38:e16. https://doi.org/10.3802/jgo.2027.38.e16
09
DOI 10.3802/jgo.2027.38.e20
Open DOI
Survey on the current status of novel cancer drug therapies for gynecological cancers in Japan: a nationwide survey by the Japan Society of Obstetrics and Gynecology (JSOG)
Kobayashi Y, et al. J Gynecol Oncol. 2027 ;38:e20. https://doi.org/10.3802/jgo.2027.38.e20
10
DOI 10.3802/jgo.2027.38.e19
Open DOI
Clinicopathologic features and outcomes of patients with microsatellite instability-high endometrial cancer treated with pembrolizumab in Japan: the KCOG-G1902S/1903S study
Kashima Y, et al. J Gynecol Oncol. 2027 ;38:e19. https://doi.org/10.3802/jgo.2027.38.e19
Bibliographical & Catalog Notes
Description based on: Vol. 20, no. 1 (Mar. 2009); title from cover.
Latest issue consulted: Vol. 20, no. 1 (Mar. 2009).
Print issues ceased with v. 26 (2015).
Also issued online.